EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Covalent Bruton tyrosine kinase inhibitors across generations: A focus on zanubrutinib

Alessandro Broccoli iD, Marzia Del Re, Romano Danesi, Pier Luigi Zinzani

Journal of Cellular and Molecular Medicine · 2025-02 · 29 (3)

DOI: 10.1111/jcmm.70170 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 31.01.2025. Verfasst von Alessandro Broccoli und 3 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy. Hauptthemen laut MEDLINE: Agammaglobulinaemia Tyrosine Kinase, Protein Kinase Inhibitors, Pyrazoles, Pyrimidines. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bruton tyrosine kinase (BTK), the primary target of BTK inhibitors, is a key enzyme in the proliferation and survival pathway of neoplastic B‐cells. BTK inhibitors are approved in many hematologic malignancies: chronic lymphocytic leukaemia, mantle cell lymphoma, marginal zone lymphoma, Waldenström macroglobulinaemia and follicular lymphoma. Second‐generation BTK inhibitors display high target selectivity thus resulting in a reduction in off‐target and off‐tissue effects, better therapeutic index and improved tolerability. This paper summarizes the mechanisms of action of first and second generation BTK inhibitors and elucidates results in any disease setting, with a precise focus on zanubrutinib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Agammaglobulinaemia Tyrosine KinaseProtein Kinase InhibitorsPyrazolesPyrimidinesPiperidinesHematologic NeoplasmsHumansAnimalsAntineoplastic AgentsTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

BTK inhibitorsWaldenstrom macroglobulinemiachronic lymphocytic leukemiafollicular lymphomamantle cell lymphomamarginal zone lymphomazanubrutinib

Substanzen

zanubrutinibAgammaglobulinaemia Tyrosine KinaseProtein Kinase InhibitorsPyrazolesPyrimidinesPiperidinesBTK protein, humanAntineoplastic AgentsTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
  • Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy.
  • Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Department of Oncology and Hemato-Oncology, University of Milano, Milan, Italy.

ORCID-Profile: Alessandro Broccoli

Zitieren

APA

Broccoli, A., Del Re, M., Danesi, R., & Zinzani, P. L. (2025). Covalent Bruton tyrosine kinase inhibitors across generations: A focus on zanubrutinib. Journal of Cellular and Molecular Medicine, 29(3). https://doi.org/10.1111/jcmm.70170

Vancouver

Broccoli A, Del Re M, Danesi R, Zinzani PL. Covalent Bruton tyrosine kinase inhibitors across generations: A focus on zanubrutinib. Journal of Cellular and Molecular Medicine. 2025;29(3). doi:10.1111/jcmm.70170

BibTeX
@article{Broccoli2025,
  author = {Broccoli, Alessandro and Del Re, Marzia and Danesi, Romano and Zinzani, Pier Luigi},
  title = {Covalent Bruton tyrosine kinase inhibitors across generations: A focus on zanubrutinib},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2025},
  volume = {29},
  number = {3},
  doi = {10.1111/jcmm.70170}
}
Kostenlos starten →